Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Papillary RCC

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    84 result(s) found for: Papillary RCC. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2016-000706-12 Sponsor Protocol Number: SUNNIFORECAST Start Date*: 2017-01-23
    Sponsor Name:Goethe University Frankfurt
    Full Title: A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell ...
    Medical condition: The primary objective of the study is to compare the of OS rate at 12 months of Nivolumab combined with Ipilimumab to Standard of Care in patients with previously untreated and advanced non-clear c...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) NL (Ongoing) CZ (Completed) BE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-004351-75 Sponsor Protocol Number: MK-3475-564 Start Date*: 2017-05-31
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
    Medical condition: Treatment of participants with RCC in the adjuvant setting
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10038395 Renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) GB (Completed) PL (Trial now transitioned) ES (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013219-37 Sponsor Protocol Number: AV-951-09-301 Start Date*: 2010-02-02
    Sponsor Name:AVEO Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
    Medical condition: Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10038410 Renal cell carcinoma recurrent LLT
    12.0 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Ongoing) PL (Completed) CZ (Completed) IT (Ongoing) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002097-30 Sponsor Protocol Number: A6181037 Start Date*: 2005-10-12
    Sponsor Name:PFIZER Inc 235 East 42nd Street, New York, NY, 10017
    Full Title: A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO...
    Medical condition: Histopathologically confirmed renal cell carcinoma with metastases
    Disease: Version SOC Term Classification Code Term Level
    8.0 10038415 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) HU (Completed) SE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) SI (Completed) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003607-30 Sponsor Protocol Number: AV-951-15-303 Start Date*: 2016-04-21
    Sponsor Name:AVEO PHARMACEUTICALS, INC.
    Full Title: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma
    Medical condition: Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) DK (Completed) ES (Completed) HU (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002667-13 Sponsor Protocol Number: PREST Start Date*: 2008-09-15
    Sponsor Name:University Clinic of Heidelberg
    Full Title: A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar®) in patients who are candidates for a curative surgery of renal cell cancer (PREST = pr...
    Medical condition: non metastatic renal tumors (RCC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000107-28 Sponsor Protocol Number: 11726 Start Date*: 2008-04-15
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC)
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012010-52 Sponsor Protocol Number: mRCC Start Date*: 2009-08-04
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma
    Medical condition: Patient with previously untreated Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006181-28 Sponsor Protocol Number: CRAD001LFR08 Start Date*: 2009-04-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer
    Medical condition: Patients who have metastatic papillary cancer of the kidney and have not received prior systemic treatment for their metastatic RCC. This multicenter international trial will enroll a maximum of 60...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000163-53 Sponsor Protocol Number: EV-2101 Start Date*: 2022-05-25
    Sponsor Name:EverImmune SAS
    Full Title: A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS
    Medical condition: Metastatic Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038395 Renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020965-26 Sponsor Protocol Number: VEG113387 Start Date*: 2010-10-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nep...
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) DK (Completed) IE (Completed) CZ (Completed) ES (Completed) BE (Completed) GR (Completed) GB (Completed) AT (Completed) PL (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004695-35 Sponsor Protocol Number: CA209-8Y8 Start Date*: 2019-06-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- ...
    Medical condition: Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) PT (Completed) GR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000502-29 Sponsor Protocol Number: WO41994 Start Date*: 2020-09-01
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERAB...
    Medical condition: Renal cell carcinoma (RCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038395 Renal carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038400 Renal carcinoma stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) GR (Completed) PL (Trial now transitioned) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002329-39 Sponsor Protocol Number: RE06 Start Date*: 2018-01-08
    Sponsor Name:University College London
    Full Title: Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage randomised controlled platform trial of adjuvant therapy in patients with r...
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003200-39 Sponsor Protocol Number: CA045-011 Start Date*: 2022-02-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Study to Compare Bempegaldesleukin Combined with Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI alone in Participants with Previously Untreated Advanced or Metasta...
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    11.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038408 Renal cell carcinomas HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006079-19 Sponsor Protocol Number: RE05 Start Date*: 2007-04-02
    Sponsor Name:University College London
    Full Title: A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) BE (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003065-15 Sponsor Protocol Number: VEG115232 Start Date*: 2013-04-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib
    Medical condition: advanced or metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-005651-21 Sponsor Protocol Number: ONC001-CL-001 Start Date*: 2021-05-26
    Sponsor Name:Oncorena AB
    Full Title: A phase I/II, open label, single arm study on safety, tolerability and anti -tumour efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma
    Medical condition: Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC) and with End-Stage Renal Disease (ESRD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    22.0 100000004857 10038443 Renal failure and impairment HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019966-95 Sponsor Protocol Number: CRAD001L2402T Start Date*: 2011-01-13
    Sponsor Name:Duke University
    Full Title: A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
    Medical condition: Histologically confirmed advanced Renal Cell Carcinoma, with non-clear cell pathology.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003905-24 Sponsor Protocol Number: AP311736 Start Date*: 2014-02-12
    Sponsor Name:SFJ Pharma Ltd. II
    Full Title: ADJUVANT AXITINIB TREATMENT OF RENAL CANCER: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT AXITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RCC
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:30:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA